Off-Label Dissemination Keeps FDA Stuck Between Prosecutors And Firms

As industry weighs the potential impact of FDA's guidance on good reprint practices, stakeholders are suggesting alternate policy approaches that could give companies sufficient clarity on how to conduct off-label dissemination